Tag: Cancer: Prostate
Mortality Risk High for Some Gleason Grade 1 Prostate Cancer Patients
Risks increased for those with percentage positive biopsies >50 percent or prostate-specific antigen >20 ng/mL
Prostate Cancer Outcomes Comparable for Transgender Women, Cisgender Men
No significant associations seen between transgender identity and metastatic presentation, high-risk localized disease
Neighborhood Disadvantage Metrics Tied to Stress Genes in Prostate Cancer
Expression of several stress-related genes increased in prostate tumors for men living in disadvantaged neighborhoods
Out-of-Pocket Costs Considerable, Increasing for Prostate Cancer Diagnostic Testing
Costs increased between 2010 and 2020 for follow-up diagnostic testing after prostate-specific antigen-based screening
18F-PSMA-1007 PET/CT Superior to MRI for Staging Prostate Cancer
PSMA PET superior to MRI for correct identification of dominant nodule, laterality, and extracapsular extension
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
The extent of cancer systemically underestimated by cognitively defined cancer contours
Black Patients More Likely to Experience MACE After ADT for Prostate Cancer
Social vulnerability index mediated 98 percent of the disparity in MACE risk between Black and White patients
Dementia With Lewy Bodies Risk Down With α-1 Adrenergic Receptor Antagonists
Risk for developing DLB was lower for men newly started on Tz/Dz/Az compared with those taking tamsulosin or 5ARI
First-Line Biparametric MRI Less Cost-Effective Than PSA for Prostate Cancer Screening
First-line PSA screening remained cost-effective even if bpMRI was free and all men with low-risk prostate cancer underwent surveillance
Active Surveillance Effective Strategy for Favorable-Risk Prostate Cancer
At 10 years after diagnosis, estimated rates of metastasis and prostate cancer-related death were 1.4 and 0.1 percent
